A State-by-State Profile of ADAPs: Key Access & Budget Categories (as of July 1997)

State	Financial Eligibility *1 (% above federal poverty level)	Medical Eligibility *2 (CD4=CD4 cell count, vl=viral load)	Protease Inhibitors Covered *3 (4 drugs approved)	Non- nucleosides Covered (2 drugs approved)	OI Prophylaxis Covered *4 (14 drugs recom- mended)	Other Medications Covered	Total Est. Budget (FY 1997)	State Contri- bution as % of Total Est. Budget (FY 1997)	ADAP Clients Served Per Month *5 (December 1996)	Emergency Cost-Containment Measures (1996- 1997) * = measure in place as of July 1997
Alabama	250%	CD4 <500	3	0	5	0	$3,190,000	5%	700	Capped enrollment*, waiting list
Alaska	200%		4	1	0	0	$122,917	0%	9	Capped enrollment*, transferred funds from other accounts, waiting list
Arizona	200%		4	0	2	2	$2,300,027	0%	354	Transferred funds from other accounts
Arkansas	100%		0	0	3	3	$1,254,013	0%	389	Capped enrollment
California	400%		4	1	13	28	$87,111,105	46%	7,342
Colorado	185%		4	0	0	0	$2,904,932	10%	423	Transferred funds from other accounts
Connecticut	300%		3	0	12	42	$3,814,283	0%	548
Delaware	230%		3	1	6	27	$979,000	0%	62
D.C.	300%		3	1	11	25	$4,363,341	3%	699	Access to protease inhibitors capped*; capped enrollment*; reduced formulary*, transferred funds from other accounts, waiting list
Florida	200%	CD4 <500	4	1	6	2	$24,317,997	0%	4,565	Access to protease inhibitors capped*
Georgia	125%	CD4 <500	3	0	0	0	$9,379,959	3%	984	Capped enrollment*; restricted access to protease inhibitors*, waiting list
Hawaii	400%		4	1	12	13	$1,112,403	27%	66
Idaho	400%	CD4 <500	1	0	2	2	$193,000	0%	30
Illinois	200%		4	1	14	36	$14,514,522	57%	1,211	Per client dollar limits on drug costs*; reduced formulary*, transferred funds from other accounts, access to protease inhibitors capped
Indiana	300%	CD4 <500	4	1	5	4	$2,310,710	3%	225	Capped enrollment*; reduced formulary*, waiting list
Iowa	200%		3	0	6	6	$292,680	0%	39
Kansas	300%		4	0	8	14	$738,196	0%	56	Transferred funds from other accounts, capped enrollment, access to protease inhibitors capped
Kentucky	300%	CD4 <550	4	1	5	7	$994,321	9%	173	Access to protease inhibitors capped*, waiting list
Louisiana	200%		3	0	0	0	$19,371,330	83%	115	Transferred funds from other accounts
Maine	200%	CD4 <400 or vl >20k	4	0	5	1	$389,426	15%	45	Access to protease inhibitors capped*, transferred funds from other accounts, waiting list
Maryland	$8,750 - $29,400		4	1	11	11	$6,259,239	10%	406
Massachusetts	<$27,000 p.a.		4	1	10	9	$7,970,714	46%	1,074	Transferred funds from other accounts
Michigan	185%	<500 CD4	4	1	6	5	$3,258,921	0%	178
Minnesota	300%		4	1	10	22	$841,003	0%	231
Mississippi	200%	CD4 <500 or vl >30k	1	0	6	2	$2,040,326	0%	415	Access to protease inhibitors capped*, reduced formulary*, transferred funds from other accounts
Missouri	185%		4	1	12	47	$2,575,652	23%	842	Access to protease inhibitors capped*, waiting list
Montana	Need-based		4	0	0	1	$204,000	0%	18	Capped enrollment*, waiting list
Nebraska	200%		4	1	6	12	$300,000	0%	59	Reduced formulary
Nevada	200%	CD4<500	0	0	5	0	$1,534,199	0%	151	Capped enrollment*, waiting list
New Hampshire	300%		4	1	10	16	$403,500	0%	40	Restrictions on some formulary drugs*, access to protease inhibitors capped
New Jersey	<$30,000 p.a.		3	1	11	19	$16,753,868	4%	1,325	Reduced formulary*
New Mexico	300%		4	1	9	20	$1,340,212	55%	375	Transferred funds from other accounts
New York	<$44,000 p.a.		4	2	14	182	$82,501,058	15%	6,183	Transferred funds from other account, reduced formulary
North Carolina	125%		4	2	10	7	$3,710,201	20%	310
North Dakota	150%		4	0	13	37	$94,390	0%	14
Ohio	281%		4	1	6	5	$6,600,000	45%	424
Oklahoma	150%		3	0	6	2	$1,690,187	12%	243	Access to protease inhibitors capped*; per client dollar limits on drug costs*, waiting list
Oregon	250%		0	0	2	2	$2,035,136	0%	99
Pennsylvania	<$30,000 p.a.		3	0	13	30	$9,871,022	47%	1,125
Puerto Rico	certified as indigent	CD4 <500 or vl >10k	3	0	13	87	$15,619,324	46%	2,320
Rhode Island	400%		4	1	9	5	$792,972	0%	57
South Carolina	300%	CD4 <500	3	0	6	6	$3,386,578	15%	198	Capped enrollment*, transferred funds from other accounts, waiting list
South Dakota	300%		0	1	8	19	$105,343	0%	30	Per client dollar limits on drug costs*; capped enrollment*; reduced formulary* , waiting list
Tennessee	300%		3	0	7	4	$1,830,152	0%	147	Restrictions on use of protease inhibitors*
Texas	200%		4	1	8	4	$17,088,684	16%	2,727	Reduced formulary*; restrictions on formulary drugs*, transferred funds from other accounts
Utah	100%		4	1	0	0	$843,006	14%	79	Transferred funds from other accounts
Vermont	200%		4	1	12	14	$374,611	20%	43	Reduced formulary*, waiting list, access to protease inhibitors capped
Virginia	200%		4	0	7	1	$6,457,969	11%	700	Reduced formulary*, waiting list, access to protease inhibitors capped
Washington	370%		3	1	10	42	$6,863,160	61%	430	transferred funds from other accounts, access to protease inhibitors capped, capped enrollment
West Virginia	300%		4	1	2	5	$361,000	7%	39	Transferred funds from other accounts
Wisconsin	200%		4	1	6	3	$1,500,001	20%	139
Wyoming	300%		4	0	13	36	$80,940	0%	44	Per client dollar limits on drug costs*, waiting list, capped enrollment

*1 Financial elgibility requirements listed are for a household of one. For more financial eligibility information, including asset limits and sliding scale co-pays, see the full NASTAD/ATDN Technical Report.

*2 All states require a diagnosis of HIV infection for ADAP enrollment.

*3 All state ADAPs cover the five nucleoside analog antiretroviral drugs (AZT, ddI, ddC, d4T, 3TC), except Louisiana where a separate state program provides these drugs through ambulatory care sites.

*4 Based on 1997 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections for Persons Infected with HIV (released June 27, 1997 MMWR, Vol. 46, No. RR-12).

*5 The number of clients served is usually fifty percent or less of the total enrollment for the month (percentage varies from state to state).
Return to top

State AIDS Drug Assistance Programs: A National Status Report on Access:
Press Release | Report | State Data |